-
Eur Radiol: What exactly is liver cell liver cancer without fast-forwarding and fast-out?
Time of Update: 2021-01-30
The qualitative diagnosis of hepatocellular liver cancer (HCC) does not require biopsy to a great extent, and the qualitative diagnosis can be achieved by relying solely on imaging characteristics. a
-
Lancet: Multi-center prospective cohorts in 82 countries - global differences in postoperative mortality and complications from cancer
Time of Update: 2021-01-30
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
-
Platinum-sensitive recurrence ovarian cancer maintenance treatment: How to choose?
Time of Update: 2021-01-30
this should be combined with the associated BRAC1/2 mutation and HD status, as well as the possible clinical benefits of PARPi, before selecting a platinum-sensitive recurrence ovarian cancer maintenance programme.
-
New use of old medicine || The role of lysole in the treatment of advanced ovarian cancer
Time of Update: 2021-01-30
two major retrospective studies documented the clinical benefits of receiving lysole maintenance therapy after standard treatment (primary surgery and complementary chemotherapy) for women who were first diagnosed with stage II-IV low-grade slurry ovarian cancer.
-
Br J Cancer: Targeted cell autophagy improves the production of PARP inhibitor resistance in breast cancer treatment
Time of Update: 2021-01-30
in breast cancer patients with BRCA mutations, PARP inhibitors (PARPis) show potential single-drug anti-tumor efficacy.
inhibition of macrocellular autophagy led to a significant increase in cell autophagy levels in the BRCA-WT breast cancer cell line treated with talazoparib by researchers who treated PARPi.
-
MSI/IHC and PREMM5 screen for Lynch syndrome-related colorectal and endometrial cancer
Time of Update: 2021-01-30
doi:10.1200/JCO.20.01470) for MSI/IHC tumor testing and clinical prediction models can effectively screen LS-related CRCs and EC, but their ability to identify non-LS-form genetic risks has not yet been evaluated.
-
Relapsed ovarian cancer: Paboli pearl monoantigen anti-combined beval bead monoantigen and cyclophosphamide treatment is safe and effective
Time of Update: 2021-01-30
Zsiros of the Roswell Park Comprehensive Cancer Center in the United States, among others, reported good resistance to Pablic beading and oral cyclophosphamide in this Phase II non-randomized clinical trial, with a clinical benefit rate of 95.0% and a continuous remission rate of 25.0% in patients with relapsed ovarian cancer.
-
Eur Radiol: How is head and neck tumor combined with amyopathy evaluated?
Time of Update: 2021-01-30
currently clinically diagnoses dystrophic disease using the cross-axis area (CSA) indicator of the 3rd cervical vertebrae (C3) horizontal cervical muscle in the CT image of the neck.
-
Proteomics analysis of endometrial cancer, pushing for personalized treatment of endometrial cancer
Time of Update: 2021-01-30
, controlled by genetic coding instructions, protein levels in cancer cells are functional results that affect gene changes in the risk of endometrial cancer, the researchers said.
-
Endometrial cancer ovaries: go or stay?
Time of Update: 2021-01-30
Li Lin collected 20 patients with stage I endometrial cancer under 40 years of age, analyzed that there was no significant difference in clinical prognosis, and concluded that the retention of ovaries had no significant effect on the survival of young patients with endometrial-like adenocarcinoma with good differentiation.
-
Lancet: Postoperative complications are the most important factor in postoperative death in patients with tumors in low- and middle-income countries
Time of Update: 2021-01-30
found that in low- and middle-income countries, cancer patients have higher mortality rates after surgery, and postoperative complications are the most important factor in patient death.
-
COVID-19 || Effects on tumor treatment and research
Time of Update: 2021-01-30
studies have looked at whether systemic anti-cancer treatments, such as chemotherapy and targeted therapy, increased COVID-19 susceptivity in patients.
researchers believe this is an add-on that could be used as part of future clinical studies to reduce trial costs and promote new treatments for patients.
-
Nat Med: Androgen-like: anti-cancer factor for estrogen-positive breast cancer
Time of Update: 2021-01-30
In this study, researchers used a variety of clinically relevant cell line models and patient derivative models to confirm that AR activation rather than inhibition plays an effective anti-tumor activity in a variety of diseases, including resistance to ER and CDK4/6 inhibitors in standard treatments.
-
Recurrence of low-grade slurry ovarian cancer: KRAS mutation predicts the benefit of THEK inhibitor Binimetinib
Time of Update: 2021-01-30
An analysis of MILO studies by Grisham and others at memorial Sloan Kettering Cancer Center in the United States showed that KRAS mutations predicted the benefits of THEK inhibitor Binimetinib, and that KRAS mutation patients benefited from nearly 7 months of progression-free survival.
-
Ann Surg: A long-term (18-year) prognostication of the LONG-term Barrett esother for AS-DD surgery!
Time of Update: 2021-01-30
The prospective study aims to assess the long-term efficacy of acid suppression-duod intestinal severity (AS-DD) surgery (including selective ecstasy neuroresisting, gastric bottom folding, gastric excision plus Roux-en-Y reconstructive surgery) to treat long-term BE (LSBE) and ultra-long-segment BE (ELSBE) to determine the histological effects of AS-DD surgery on gastroenterology and progression to EAC.
-
Guidelines for the diversion of new assisted chemotherapy for advanced ovarian cancer: high risk, high yield or gain?
Time of Update: 2021-01-30
Whether to choose new complementary chemotherapy (NACT) or first tumor cell reduction (PDS) for patients with advanced endodermal ovarian cancer (EOC) has long been a hot topic in the gynaecological o
-
Recurrence of lymph nodes after epitheliotic ovarian cancer peritina: prognosis factors and treatment outcomes
Time of Update: 2021-01-30
patients in the RLN recurrence group who received 4 or more chemotherapy options (20/30, 66.7%) were significantly more likely than those in the IP group and the joint relapse group (29/66 (43.9%) and 18/39 (46.15%).
-
Clin Cancer Res: Inhibiting FGFR overcomes skin squamous cell carcinoma resistance to EGFR targeted therapy
Time of Update: 2021-01-30
Giffeitinib inhibits the growth of PIC3CA mutation cSCC without EGFR and RAS gene mutations, Gifinistinib therapy can significantly block the growth of epithirsty cSCC-PDX tumors, while tumors carrying PIK3CA activation mutations (E545K) are resistant to Gifetinib treatment.
-
Frost, or the ultimate star of cancer!
Time of Update: 2021-01-30
Studies have suggested that short- and long-term exposure to arsenic can also cause other health problems, such as workers who are regularly exposed to arsenic trioxide (e.g. working in a metal refinery), residents who regularly drink water high in arsenic (0.3-0.4 ppm), and patients who take arsenic-based drugs for long periods of time.
-
Heavy! Lilly's new breast ® (Abesili tablets) approved in China!
Time of Update: 2021-01-30
Lilly Pharmaceuticals recently announced that its new anti-tumor drug ® (Abesili tablets) was approved by the State Drug Administration (NMPA) on December 29, 2020 for hormone-positive hormone (HR), human skin growth factor 2 (HER2) negative local late stage or metastatic breast cancer: (1) in combined with aromatase inhibitors as an initial endocrine treatment in post-menstrual female patients.
